| Biotechnology feed | All feeds
This point mutation... Pharmacy Choice: Feb 11 2010 10:21PM Matching: melas Find similar documents
9, 2010 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co.
today announced that it has initiated a Phase IIa clinical trial for A0001 in patients with the A3243G mitochondrial DNA point mutation and evidence of impaired mitochondrial... Interest!ALERT: Feb 9 2010 5:30PM Matching: melas Find similar documents
Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.
All rights reserved. All other trademarks recognized. Copyright 1997-2009 - BioPortfolio Limited.